SCHEMBL6038356

SCHEMBL6038356

O=S(=O)(Nc1nccnc1OCc1ccccn1)c1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
AR P10275 1/20 0.44
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PTGS2 P35354 1/20 0.43
KDM4E B2RXH2 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
PKM P14618 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PRMT1 Q99873 1/20 0.41
CCR4 P51679 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038494 0.88 KMT2A (0.50) MEN1KMT2AARALDH1A1L3MBTL1
SCHEMBL6038732 0.86 KMT2A (0.48) MEN1KMT2AALDH1A1L3MBTL1HTT
SCHEMBL6038381 0.85 KDM4E (0.56) MEN1KMT2AARALDH1A1L3MBTL1
SCHEMBL6039048 0.85 MEN1 (0.49) MEN1KMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL6038503 0.84 MEN1 (0.47) MEN1KMT2AALDH1A1L3MBTL1HTT
SCHEMBL6039079 0.81 HTT (0.55) MEN1KMT2AARALDH1A1L3MBTL1
SCHEMBL6039126 0.80 AR (0.50) MEN1KMT2AARALDH1A1L3MBTL1
SCHEMBL6039013 0.79 SCN9A (0.50) MEN1KMT2AARHTTSMN1; SMN2
SCHEMBL6038939 0.79 AR (0.49) MEN1KMT2AARALDH1A1L3MBTL1
SCHEMBL6184367 0.79 KDM4E (0.55) MEN1KMT2AALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885AR 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.